Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Janssen Vaccines & Prevention B v patents


Recent patent applications related to Janssen Vaccines & Prevention B v. Janssen Vaccines & Prevention B v is listed as an Agent/Assignee. Note: Janssen Vaccines & Prevention B v may have other listings under different names/spellings. We're not affiliated with Janssen Vaccines & Prevention B v, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "J" | Janssen Vaccines & Prevention B v-related inventors


Method for the production of ad26 adenoviral vectors

Described are methods for large-scale production of recombinant adenovirus 26, utilizing perfusion systems and infection at very high cell densities.... Janssen Vaccines & Prevention B v

Trimer stabilizing hiv envelope protein mutations

Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or... Janssen Vaccines & Prevention B v

Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.... Janssen Vaccines & Prevention B v

Assays for recombinant expression systems

The invention is a method for assessing protein expression by recombinant expression systems. The method uses mass spectrometry to quantify protein expression. The method has particular application in potency testing of vaccine compositions.... Janssen Vaccines & Prevention B v

Binding molecules directed against influenza hemagglutinin and uses thereof

Monomeric and multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains including HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus... Janssen Vaccines & Prevention B v

Human neutralizing antibodies binding to influenza neuraminidase

Influenza neuraminidase (NA)-binding human antibodies, which are capable of neutralizing at least one influenza A virus strain containing NA of the N1 subtype, and antigen-binding fragments thereof are described. Certain antibodies or antigen-binding fragments described herein furthermore are capable of neutralizing at least one influenza A virus strain comprising NA... Janssen Vaccines & Prevention B v

Method for quantification of virus particles using capillary zone electrophoresis

The present invention provides a method for the quantification of virus particles in a biological sample, comprising the steps of: (a) introducing said biological sample comprising virus particles into a capillary tube containing a buffer solution; (b) applying an electrical field to said capillary tube of sufficient voltage to allow... Janssen Vaccines & Prevention B v

Therapeutic hpv18 vaccines

Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV18 and/or HPV16.... Janssen Vaccines & Prevention B v

Hiv vaccine formulation

Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the... Janssen Vaccines & Prevention B v

Methods and compositions for enhancing immune responses

Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an MVA vector as a prime and an adenovirus vector as a boost and is characterized by a high level of antibody response specific to... Janssen Vaccines & Prevention B v

Meningitis b vaccine

Compositions, including vaccine compositions, are provided comprising outer membrane vesicles (OMVs) from N. meningitidis B (MenB). Also provided are methods of making such compositions comprising growing MenB in culture and isolating the OMVs produced, and the use of MenB vaccine compositions for prevention of meningitis in a subject.... Janssen Vaccines & Prevention B v

Methods and compositions for inducing protective immunity against filovirus infection

The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.... Janssen Vaccines & Prevention B v

Therapeutic hpv16 vaccines

Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV16.... Janssen Vaccines & Prevention B v

Influenza virus vaccines and uses thereof

Provided herein are influenza hemagglutinin stem domain polypeptides, methods for providing hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and/or treatment of influenza... Janssen Vaccines & Prevention B v

Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.... Janssen Vaccines & Prevention B v

Influenza virus vaccines and uses thereof

Provided herein are multimeric influenza hemagglutinin stem domain polypeptides, methods for providing hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and/or treatment of influenza... Janssen Vaccines & Prevention B v

Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof

Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.... Janssen Vaccines & Prevention B v

Process for the purification of poliovirus from cell cultures

The disclosure provides methods for poliovirus purification from crude cell culture harvests using a detergent followed by a clarification step.... Janssen Vaccines & Prevention B v

Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.... Janssen Vaccines & Prevention B v

Therapeutic hpv18 vaccines

Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV18 and/or HPV16.... Janssen Vaccines & Prevention B v








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Janssen Vaccines & Prevention B v in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Janssen Vaccines & Prevention B v with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###